Genotyping FcɣRs Genes of HIV-1 Patients "Progressor": Correlation With the Changing Profile of the Infection
- Conditions
- HIV Infection
- Registration Number
- NCT03130296
- Lead Sponsor
- University Hospital, Strasbourg, France
- Brief Summary
This non-interventional study aims to determine whether there is a correlation between the Fc receptor polymorphism (FcR) and the course of the disease following HIV infection.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 230
Inclusion Criteria
- Patient aged 18 or older,
- Patient affiliated to a social security scheme,
- Informed consent dated and signed by the investigating physician the patient,
- Patients infected with HIV-1 having progressed in clinical (stage C) or biologically (CD4 nadir <350 / mm3 and viral load> 10,000 copies / ml)
Exclusion Criteria
- Impossibility of giving the subject informed information (subject in an emergency situation, difficulty in understanding the subject, ...)
- Subject under safeguard of justice,
- Subject under tutelage or under curatorship,
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Correlation research between Fc receptor polymorphism (FcR) and the course of disease following HIV infection. After infection, up to 12 months
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link FcɣR polymorphisms to HIV-1 disease progression in progressor patients?
Are FcɣR gene variants associated with differential immune responses to standard antiretroviral therapies in HIV-1 progressors?
Which FcɣR biomarkers could predict HIV-1 progression rates or treatment response in longitudinal studies?
What adverse events are reported in FcɣR-related HIV-1 research and how are they managed in clinical settings?
How do FcɣR genotyping strategies compare to other immune checkpoint biomarkers in guiding HIV-1 therapeutic interventions?
Trial Locations
- Locations (1)
Le Trait d'Union - Centre de soins de l'infection par le VIH au NHC
🇫🇷Strasbourg, France
Le Trait d'Union - Centre de soins de l'infection par le VIH au NHC🇫🇷Strasbourg, FranceDavid REY, MDContact33 3 69 55 05 01David.Rey@chru-strasbourg.frChristiane MOOG, PhDContact33 3 68 85 37 42c.moog@unistra.frMaria Partisani, MDSub InvestigatorChristine Cheneau, MDSub InvestigatorMichele Priester, MDSub InvestigatorMarie Laure Batard, MDSub InvestigatorClaudine Bernard-Henry, MDSub InvestigatorChristiane Moog, PhDSub Investigator